Payal Guha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Payal Guha has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Amir Sam
Imperial College School of Medicine, Imperial College London
1 shared publication - Ann-Marie Malby Schoos
COPSAC, Copenhagen Prospective Studies on Asthma in Childhood Copenhagen University Hospital—Herlev and Gentofte Gentofte Denmark
1 shared publication Bo L. Chawes
COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital University of Copenhagen Copenhagen Denmark
1 shared publication- Celia Brown
Imperial College School of Medicine, Imperial College London
1 shared publication - Charalampos-Vlasios Stikas
Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom
1 shared publication - Chukwuma Uduku
Imperial College School of Medicine, Imperial College London
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Taylor & Francis in Medical Teacher
- p. 1-7
Teaching on demand: Exploring the role of AI in medical education podcasts
- 9 October 2026
- Published by Taylor & Francis in Medical Teacher
- p. 1-7
Open AccessTeaching on demand: Exploring the role of AI in medical education podcasts
- Open Access
- 8 March 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (5) , 526-535
Outcomes reported in randomized controlled trials for mixed and non‐IgE‐mediated food allergy: Systematic review
BackgroundMixed and non-IgE-mediated food allergy is a subset of immune-mediated adverse food reactions that can impose a major burden on the quality of life of affected patients and their families. Clinical trials to study these diseases are reliant upon consistent and valid outcome measures that are relevant to both patients and clinicians, but the degree to which such stringent outcome reporting takes place is poorly studied. ObjectiveAs part of the Core Outcome Measures for Food Allergy (COMFA) project, we identified outcomes reported in randomized clinical trials (RCT) of treatments for mixed or non-IgE-mediated food allergy. DesignIn this systematic review, we searched the Ovid, MEDLINE and Embase databases for RCTs in children or adults investigating treatments for food protein-induced enterocolitis syndrome, food protein-induced allergic proctocolitis, food protein-induced enteropathy and eosinophilic gastrointestinal disorders including eosinophilic esophagitis [EoE], eosinophilic gastritis and eosinophilic colitis published until 14 October 2022. ResultsTwenty-six eligible studies were identified, with 23 focused on EoE (88%). Most interventions were corticosteroids or monoclonal antibodies. All EoE studies assessed patient-reported dysphagia, usually using a non-validated questionnaire. Twenty-two of 23 EoE studies used peak tissue eosinophil count as the primary outcome, usually using a non-validated assessment method, and other immunological markers were only exploratory. Thirteen (57%) EoE studies reported endoscopic outcomes of which six used a validated scoring tool recently recommended as a core outcome for EoE trials. Funding source was not obviously associated with likelihood of an RCT reporting mechanistic versus patient-reported outcomes. Only 3 (12%) RCTs concerned forms of food allergy other than EoE, and they reported on fecal immunological markers and patient-reported outcomes. ConclusionsOutcomes measured in clinical trials of EoE and non-IgE-mediated food allergy are heterogeneous and largely non-validated. Core outcomes for EoE have been developed and need to be used in future trials. For other forms of mixed or non-IgE-mediated food allergies, core outcome development is needed to support the development of effective treatments. Systematic review registrationOSF public registry DOI:10.17605/OSF.IO/AZX8S
- 8 March 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (5) , 526-535
Open AccessOutcomes reported in randomized controlled trials for mixed and non‐IgE‐mediated food allergy: Systematic review
BackgroundMixed and non-IgE-mediated food allergy is a subset of immune-mediated adverse food reactions that can impose a major burden on the quality of life of affected patients and their families. Clinical trials to study these diseases are reliant upon consistent and valid outcome measures that are relevant to both patients and clinicians, but the degree to which such stringent outcome reporting takes place is poorly studied. ObjectiveAs part of the Core Outcome Measures for Food Allergy (COMFA) project, we identified outcomes reported in randomized clinical trials (RCT) of treatments for mixed or non-IgE-mediated food allergy. DesignIn this systematic review, we searched the Ovid, MEDLINE and Embase databases for RCTs in children or adults investigating treatments for food protein-induced enterocolitis syndrome, food protein-induced allergic proctocolitis, food protein-induced enteropathy and eosinophilic gastrointestinal disorders including eosinophilic esophagitis [EoE], eosinophilic gastritis and eosinophilic colitis published until 14 October 2022. ResultsTwenty-six eligible studies were identified, with 23 focused on EoE (88%). Most interventions were corticosteroids or monoclonal antibodies. All EoE studies assessed patient-reported dysphagia, usually using a non-validated questionnaire. Twenty-two of 23 EoE studies used peak tissue eosinophil count as the primary outcome, usually using a non-validated assessment method, and other immunological markers were only exploratory. Thirteen (57%) EoE studies reported endoscopic outcomes of which six used a validated scoring tool recently recommended as a core outcome for EoE trials. Funding source was not obviously associated with likelihood of an RCT reporting mechanistic versus patient-reported outcomes. Only 3 (12%) RCTs concerned forms of food allergy other than EoE, and they reported on fecal immunological markers and patient-reported outcomes. ConclusionsOutcomes measured in clinical trials of EoE and non-IgE-mediated food allergy are heterogeneous and largely non-validated. Core outcomes for EoE have been developed and need to be used in future trials. For other forms of mixed or non-IgE-mediated food allergies, core outcome development is needed to support the development of effective treatments. Systematic review registrationOSF public registry DOI:10.17605/OSF.IO/AZX8S